Official websites use .gov

A .gov website belongs to an official government organization in the United States.

Secure .gov websites use HTTPS

A lock ( 🔒 ) or https:// means you've safely connected to the .gov website. Share sensitive information only on official, secure websites.

Need Help

Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures

Award Number: K99CA248835
ORGANIZATION: NATIONAL CANCER INSTITUTE
OPDIV: NIH
AWARD CLASS: DISCRETIONARY
AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP
PERIOD OF PERFORMANCE START DATE: 03/10/2020
PERIOD OF PERFORMANCE END DATE: 02/28/2022

Group Awards By:

View Award Description

Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures - Abstract TET-family of dioxygenases mediate DNA demethylation by sequentially oxidizing 5-methylcytosine (5mC) to 5- hydroxymethyl- (5hmC), 5-formyl- (5fC) and 5-carboxyl-cytosine (5caC). TET enzymes are required for normal development and loss-of TET function due to mutations, metabolic reprogramming, hypoxia and other additional mechanisms occurs frequently in many hematological malignancies and solid tumors. Recent studies have identified mutations in TET proteins and metabolic enzymes which regulate TET catalytic activity in a large cohort of patients with Diffuse Large B-cell Lymphoma (DLBCL). However, the clinical significance of these mutations in DLBCL and the molecular mechanisms through which TET proteins suppress development of malignancies in general, is not well-understood. Studies from us and others have highlighted that TET activity is required for differentiation of mature B cells; the cell-of-origin for DLBCL. To investigate the role of TET loss-of-function in the pathogenesis of DLBCL, I recently generated mice with B-cell-specific deletion of TET2 and TET3 proteins. Deletion of TET2 and TET3 in mouse B cells caused development of aggressive lymphomas and rapid mortality. Preliminary analysis of TET-deficient B cells revealed increased genomic instability and a striking accumulation of unusual secondary DNA structures called G-quadruplexes (G-quads). The accumulation of G-quads occurred at early stages of B-cell expansion and was also a feature associated with TET-deficiency in other cellular lineages. G-quad structures have been linked to genomic instability and transcriptional alterations in cancers but their physiological functions in normal cells and pathological roles in malignant cells remain poorly understood. For the studies proposed here, I hypothesize that TET proteins function as tumor suppressors by limiting the accumulation of G-quad structures. Studies in Aim1 will examine the association of G-quad structures with TET activity, genomic instability and transcriptional alterations during TET loss-of-function induced lymphomagenesis. Aim2 will interrogate molecular mechanisms by which TET proteins limit the accumulation of G-quad structures. Aim3 will focus on delineating mechanisms by which G-quads regulate chromatin structure and function in normal and malignant B cells. Studies in Aim2 and Aim3 will be performed in R00 phase and will likely prime the emergence of many new lines of investigations. Together, these studies will use B cells as a model system to understand the mechanistic basis for the broad tumor suppressive functions of TET proteins and will reveal novel facets about the biological functions of G-quad structures. The proposal outlines a specific training plan for the K99 and R00 phases, to acquire the skillset necessary to perform the proposed studies and successfully transition to an independent position. During this process, I anticipate to develop an independent line of research through my continued training in an excellent research environment, facilitated by an outstanding mentoring team.


Issue Date FY	Funding FY	Legal Entity Name	Legal Entity Address	Legal Entity City	Legal Entity State	Legal Entity Zip Code	Legal Entity COUNTY	Legal Entity COUNTRY	Assistance Listing	Award Code	Budget Year	Action Date	Action Type	Action Amount

Issue Date FY: 2022 ( Subtotal = -$21,042 )
2022	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	001	2	7/8/2022	NON-COMPETING CONTINUATION	-$21,042
2022	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	000	2	5/27/2022	NON-COMPETING CONTINUATION	$0
														Subtotal = -$21,042

Issue Date FY: 2021 ( Subtotal = $144,720 )
2021	2021	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	000	2	2/2/2021	NON-COMPETING CONTINUATION	$144,720
														Subtotal = $144,720

Issue Date FY: 2020 ( Subtotal = $144,720 )
2020	2020	LA JOLLA INSTITUTE FOR IMMUNOLOGY	9420 ATHENA CIR	LA JOLLA	CA	92037	SAN DIEGO	USA	Cancer Research Manpower	000	1	3/10/2020	NEW	$144,720
														Subtotal = $144,720

Grand Total All Awards = $268,398

Top

All Categories

About

Search

Reports

Data Submission

Award Information

Tumor suppressive functions of TET proteins in B cell malignancies: role of G-quadruplex structures

Award Number: K99CA248835

ORGANIZATION: NATIONAL CANCER INSTITUTE

OPDIV: NIH

AWARD CLASS: DISCRETIONARY

AWARD ACTIVITY TYPE: TRAINING/TRAINEESHIP

PERIOD OF PERFORMANCE START DATE: 03/10/2020

PERIOD OF PERFORMANCE END DATE: 02/28/2022

Federal Websites

Department of Health & Human Services

HHS Operating Divisions

HHS Staff Divisions

Download A Document Viewer